NF-κB and androgen receptor variant expression correlate with human BPH progression

Prostate

Volumn 76, Issue 5, 2016, Pages 491-511

  Austin, David C ^a   Strand, Douglas W ^b   Love, Harold L ^b   Franco, Omar E ^c   Jang, Alex ^b   Grabowska, Magdalena M ^b   Miller, Nicole L ^b   Hameed, Omar ^b   Clark, Peter E ^b,d   Fowke, Jay H ^b   Matusik, Robert J ^a,d   Jin, Ren J ^b   Hayward, Simon W ^b,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

androgen receptor; androgen receptor variant 7; BPH; Inflammation; NF B

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANDROGEN RECEPTOR; ANDROGEN RECEPTOR FULL LENGTH; ANDROGEN RECEPTOR VARIANT; ANDROGEN RECEPTOR VARIANT 7; FINASTERIDE; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE 1; STEROID 5ALPHA REDUCTASE 2; STEROID 5ALPHA REDUCTASE 3; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG RESPONSE; HUMAN; HUMAN CELL; HUMAN TISSUE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM CELL; PROSTATE HYPERTROPHY; PROSTATE VOLUME; PROSTATECTOMY; PROTEIN EXPRESSION; STROMA CELL; TRANSRECTAL ULTRASONOGRAPHY; CELL SURVIVAL; DISEASE COURSE; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

AGED; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; NF-KAPPA B; PROSTATE; PROSTATIC HYPERPLASIA; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 84958766540     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.23140     Document Type: Article

References (67)

1. Platz EA, Joshu CE, Mondul AM, Peskoe SB, Willett WC, Giovannucci E,. Incidence and progression of lower urinary tract symptoms in a large prospective cohort of United States men. J Urol 2012; 2: 496-501.
2. Hammarsten J, Peeker R,. Urological aspects of the metabolic syndrome. Nat Rev Urol 2011; 9: 483-494.
3. McNeal J,. Pathology of benign prostatic hyperplasia. Insight into etiology. Urol Clin North Am 1990; 3: 477-486.
4. Rohrmann S, De Marzo AM, Smit E, Giovannucci E, Platz EA,. Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III). Prostate 2005; 1: 27-33.
5. Schenk JM, Calip GS, Tangen CM, Goodman P, Parsons JK, Thompson IM, Kristal AR,. Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: Results from the prostate cancer prevention trial. Am J Epidemiol 2012; 2: 156-163.
6. Fibbi B, Penna G, Morelli A, Adorini L, Maggi M,. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl 2010; 3: 475-488.
7. McVary KT, Rademaker A, Lloyd GL, Gann P,. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2005; 4 (Pt 1): 1327-1433.
8. Ho CK, Habib FK,. Estrogen and androgen signaling in the pathogenesis of BPH. Nat Rev Urol 2011; 1: 29-41.
9. Rodriguez-Nieves JA, Macoska JA,. Prostatic fibrosis, lower urinary tract symptoms, and BPH. Nat Rev Urol 2013; 9: 546-550.
10. Kramer G, Mitteregger D, Marberger M,. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease ? Eur Urol 2007; 5: 1202-1216.
11. Madigan AA, Sobek KM, Cummings JL, Green WR, Bacich DJ, O'Keefe DS,. Activation of innate anti-viral immune response genes in symptomatic benign prostatic hyperplasia. Genes Immun 2012; 7: 566-572.
12. Lin-Tsai O, Clark PE, Miller NL, Fowke JH, Hameed O, Hayward SW, Strand DW,. Surgical intervention for symptomatic benign prostatic hyperplasia is correlated with expression of the AP-1 transcription factor network. Prostate 2014; 6: 669-679.
13. Lepor H, Kazzazi A, Djavan B,. alpha-Blockers for benign prostatic hyperplasia: The new era. Curr Opin Urol 2012; 1: 7-15.
14. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G, Aria A, Investigators AS,. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 3: 434-441.
15. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr., Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr., Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA, G. the Medical Therapy of Prostatic Symptoms Research. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 25: 2387-2398.
16. Lu-Yao GL, Barry MJ, Chang CH, Wasson JH, Wennberg JE,. Transurethral resection of the prostate among Medicare beneficiaries in the United States: Time trends and outcomes. Prostate patient outcomes research team (PORT). Urology 1994; 5: 692-698; discussion 698-699.
17. Hu DG, Hickey TE, Irvine C, Wijayakumara DD, Lu L, Tilley WD, Selth LA, Mackenzie PI,. Identification of androgen receptor splice variant transcripts in breast cancer cell lines and human tissues. Horm Cancer 2014; 2: 61-71.
18. Ghosh S, Hayden MS,. New regulators of NF-kappaB in inflammation. Nat Rev Immunol 2008; 11: 837-848.
19. Basseres DS, Baldwin AS,. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 2006; 51: 6817-6830.
20. Toubi E, Shoenfeld Y,. Toll-like receptors and their role in the development of autoimmune diseases. Autoimmunity 2004; 3: 183-188.
21. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ,. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008; 13: 5469-5477.
22. Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Chen H, Kong X, Melamed J, Tepper CG, Kung HJ, Brodie AM, Edwards J, Qiu Y,. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 2009; 6: 2305-2313.
23. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, Bova GS, Luo J,. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009; 1: 16-22.
24. Hu R, Isaacs WB, Luo J,. A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. Prostate 2011; 15: 1656-1667.
25. Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H, Nelson PS, Plymate SR,. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 2010; 8: 2715-2730.
26. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K, Sawyers CL,. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci USA 2010; 39: 16759-16765.
27. Zhang X, Morrissey C, Sun S, Ketchandji M, Nelson PS, True LD, Vakar-Lopez F, Vessella RL, Plymate SR,. Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS ONE 2011; 11: e27970.
28. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J,. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014; 11: 1028-1038.
29. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM,. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res 2013; 2: 483-489.
30. Yu Z, Chen S, Sowalsky AG, Voznesensky OS, Mostaghel EA, Nelson PS, Cai C, Balk SP,. Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clin Cancer Res 2014; 20: 1590-1600.
31. Nadiminty N, Tummala R, Liu C, Yang J, Lou W, Evans CP, Gao AC,. NF-kappaB2/p52 induces resistance to enzalutamide in prostate cancer: Role of androgen receptor and its variants. Mol Cancer Ther 2013; 8: 1629-1637.
32. Jin R, Yamashita H, Yu X, Wang J, Franco OE, Wang Y, Hayward SW, Matusik RJ,. Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression. Oncogene 2015; 28: 3700-3710.
33. Roehrborn CG,. Definition of at-risk patients: Baseline variables. BJU Int 2006; 97 (Suppl 2): 7-11.
34. Jin R, Yamashita H, Yu X, Wang J, Franco OE, Wang Y, Hayward SW, Matusik RJ,. Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression. Oncogene 2014.
35. Franco OE, Jiang M, Strand DW, Peacock J, Fernandez S, Jackson RS 2nd, Revelo MP, Bhowmick NA, Hayward SW,. Altered TGF-beta signaling in a subpopulation of human stromal cells promotes prostatic carcinogenesis. Cancer Res 2011; 4: 1272-1281.
36. Jiang M, Strand DW, Fernandez S, He Y, Yi Y, Birbach A, Qiu Q, Schmid J, Tang DG, Hayward SW,. Functional remodeling of benign human prostatic tissues in vivo by spontaneously immortalized progenitor and intermediate cells. Stem Cells 2010; 344-356.
37. Diessenbacher P, Hupe M, Sprick MR, Kerstan A, Geserick P, Haas TL, Wachter T, Neumann M, Walczak H, Silke J, Leverkus M,. NF-kappaB inhibition reveals differential mechanisms of TNF versus TRAIL-induced apoptosis upstream or at the level of caspase-8 activation independent of cI AP2. J Invest Dermatol 2008; 5: 1134-1147.
38. Leverkus M, Sprick MR, Wachter T, Denk A, Brocker EB, Walczak H, Neumann M,. TRAIL-induced apoptosis and gene induction in HaCaT keratinocytes: Differential contribution of TRAIL receptors 1 and 2. J Invest Dermatol 2003; 1: 149-155.
39. Marienfeld R, Berberich-Siebelt F, Berberich I, Denk A, Serfling E, Neumann M,. Signal-specific and phosphorylation-dependent RelB degradation: A potential mechanism of NF-kappaB control. Oncogene 2001; 56: 8142-8147.
40. Everhart MB, Han W, Sherrill TP, Arutiunov M, Polosukhin VV, Burke JR, Sadikot RT, Christman JW, Yull FE, Blackwell TS,. Duration and intensity of NF-kappaB activity determine the severity of endotoxin-induced acute lung injury. J Immunol 2006; 8: 4995-5005.
41. Zhang J, Thomas TZ, Kasper S, Matusik RJ,. A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology 2000; 12: 4698-4710.
42. Gao N, Zhang J, Rao MA, Case TC, Mirosevich J, Wang Y, Jin R, Gupta A, Rennie PS, Matusik RJ,. The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes. Mol Endocrinol 2003; 8: 1484-1507.
43. Wilton JH, Titus MA, Efstathiou E, Fetterly GJ, Mohler JL,. Androgenic biomarker profiling in human matrices and cell culture samples using high throughput, electrospray tandem mass spectrometry. Prostate 2014; 74 (7): 722-731.
44. Strand DW, Jiang M, Murphy TA, Yi Y, Konvinse KC, Franco OE, Wang Y, Young JD, Hayward SW,. PPARgamma isoforms differentially regulate metabolic networks to mediate mouse prostatic epithelial differentiation. Cell Death Dis 2012; e361.
45. Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, Rittmaster RS,. The relationship between prostate inflammation and lower urinary tract symptoms: Examination of baseline data from the REDUCE trial. Eur Urol 2008; 6: 1379-1384.
46. Zhang L, Altuwaijri S, Deng F, Chen L, Lal P, Bhanot UK, Korets R, Wenske S, Lilja HG, Chang C, Scher HI, Gerald WL,. NF-kappaB regulates androgen receptor expression and prostate cancer growth. Am J Pathol 2009; 2: 489-499.
47. Sun F, Chen HG, Li W, Yang X, Wang X, Jiang R, Guo Z, Chen H, Huang J, Borowsky AD, Qiu Y,. Androgen receptor splice variant AR3 promotes prostate cancer via modulating expression of autocrine/paracrine factors. J Biol Chem 2014; 3: 1529-1539.
48. Parsons JK,. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: New approaches to old problems. J Urol 2007; 2: 395-401.
49. Parsons JK,. Benign prostatic hyperplasia and male lower urinary tract symptoms: Epidemiology and risk factors. Curr Bladder Dysfunct Rep 2010; 4: 212-218.
50. Chen CD, Sawyers CL,. NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol Cell Biol 2002; 8: 2862-2870.
51. Strand DW, Degraff DJ, Jiang M, Sameni M, Franco OE, Love HD, Hayward WJ, Lin-Tsai O, Wang AY, Cates JM, Sloane BF, Matusik RJ, Hayward SW,. Deficiency in metabolic regulators PPARgamma and PTEN cooperates to drive keratinizing squamous metaplasia in novel models of human tissue regeneration. Am J Pathol 2013; 2: 449-459.
52. Saigal CS, Joyce G,. Economic costs of benign prostatic hyperplasia in the private sector. J Urol 2005; 4: 1309-1313.
53. Wei JT, Calhoun E, Jacobsen SJ,. Urologic diseases in America project: Benign prostatic hyperplasia. J Urol 2005; 4: 1256-1261.
54. Arrighi HM, Metter EJ, Guess HA, Fozzard JL,. Natural history of benign prostatic hyperplasia and risk of prostatectomy. The Baltimore longitudinal study of aging. Urology 1991; 38 (1 Suppl): 4-8.
55. Parsons JK, Carter HB, Partin AW, Windham BG, Metter EJ, Ferrucci L, Landis P, Platz EA,. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 2006; 7: 2562-2568.
56. Schenk JM, Kristal AR, Arnold KB, Tangen CM, Neuhouser ML, Lin DW, White E, Thompson IM,. Association of symptomatic benign prostatic hyperplasia and prostate cancer: Results from the prostate cancer prevention trial. Am J Epidemiol 2011; 12: 1419-1428.
57. Roehrborn CG,. Combination medical therapy for lower urinary tract symptoms and benign prostatic hyperplasia. Rev Urol 2005; S43-S51.
58. Breyer BN, Sarma AV,. Hyperglycemia and insulin resistance and the risk of BPH/LUTS: An update of recent literature. Curr Urol Rep 2014; 12: 462.
59. Maestroni GJ,. Dendritic cell migration controlled by alpha 1b-adrenergic receptors. J Immunol 2000; 12: 6743-6747.
60. Heijnen CJ, Rouppe van der Voort C, van de Pol M, Kavelaars A,. Cytokines regulate alpha(1)-adrenergic receptor mRNA expression in human monocytic cells and endothelial cells. J Neuroimmunol 2002; 1-2: 66-72.
61. Perez DM, Papay RS, Shi T,. Alpha1-Adrenergic receptor stimulates interleukin-6 expression and secretion through both mRNA stability and transcriptional regulation: Involvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB. Mol Pharmacol 2009; 1: 144-152.
62. Farmer P, Pugin J,. beta-adrenergic agonists exert their "anti-inflammatory" effects in monocytic cells through the IkappaB/NF-kappaB pathway. Am J Physiol Lung Cell Mol Physiol 2000; 4: L675-L682.
63. Romero-Sandoval EA, McCall C, Eisenach JC,. Alpha2-adrenoceptor stimulation transforms immune responses in neuritis and blocks neuritis-induced pain. J Neurosci 2005; 39: 8988-8994.
64. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES,. The sympathetic nerve-an integrative interface between two supersystems: The brain and the immune system. Pharmacol Rev 2000; 4: 595-638.
65. McNeal JE,. Prostate anatomy and BPH morphogenisis. Prog Clin Biol Res 1984; 27-54.
66. Hayward SW, Haughney PC, Rosen MA, Greulich KM, Weier HU, Dahiya R, Cunha GR,. Interactions between adult human prostatic epithelium and rat urogenital sinus mesenchyme in a tissue recombination model. Differentiation 1998; 3: 131-140.
67. Eferl R, Wagner EF,. AP-1: A double-edged sword in tumorigenesis. Nat Rev Cancer 2003; 11: 859-868.